Kenneth Gordon

7PUBLICATIONS
24CO-AUTHORS
AllergyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PharmacogenomicsToxicology (incl. clinical toxicology)Rheumatology and arthritis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 10, 2025
Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions.

Kenneth B Gordon, Yayoi Tada, Milan J Anadkat

|Mar 20, 2024
Bimekizumab for the treatment of psoriasis.

Molly Thapar, Milan Patel, Kenneth Gordon

|Nov 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.

Kenneth B Gordon, Richard G Langley, Richard B Warren

|Oct 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

K B Gordon, M Lebwohl, K A Papp

|Jun 09, 2021
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.

K Reich, K B Gordon, B E Strober

|Sep 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.

Kristian Reich, April W Armstrong, Peter Foley

Pageof 2

Frequent Collaborators

3 joint publications

Kristian Reich

3 joint publications

Diamant Thaçi

2 joint publications

April W Armstrong

2 joint publications

Megan Miller